Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies

Despite a strong preclinical rationale for targeting the insulin-like growth factor (IGF) axis in cancer, clinical studies of IGF-1 receptor (IGF-1R)-targeted monotherapies have been largely disappointing, and any potential success has been limited by the lack of validated predictive biomarkers for patient enrichment. A large body of preclinical evidence suggests that the key role of the IGF axis in cancer is in driving treatment resistance, via general proliferative/survival mechanisms, interactions with other mitogenic signaling networks, and class-specific mechanisms such as DNA damage repair. Consequently, combining IGF-targeted agents with standard cytotoxic agents, other targeted agents, endocrine therapies, or immunotherapies represents an attractive therapeutic approach. Anti-IGF-1R monoclonal antibodies (mAbs) do not inhibit IGF ligand 2 (IGF-2) activation of the insulin receptor isoform-A (INSR-A), which may limit their anti-proliferative activity. In addition, due to their lack of specificity, IGF-1R tyrosine kinase inhibitors are associated with hyperglycemia as a result of interference with signaling through the classical metabolic INSR-B isoform; this may preclude their use at clinically effective doses. Conversely, IGF-1/IGF-2 ligand-neutralizing mAbs inhibit proliferative/anti-apoptotic signaling via IGF-1R and INSR-A, without compromising the metabolic function of INSR-B. Therefore, combination regimens that include these agents may be more efficacious and tolerable versus IGF-1R-targeted combinations. Herein, we review the preclinical and clinical experience with IGF-targeted therapies to-date, and discuss the rationale for future combination approaches as a means to overcome treatment resistance.

• Publication year

  2017

• Venue

  Targeted oncology

• Publication date

  2017-08-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11523-017-0514-5PMID 28815409PMCID 5610669
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CURRENT STATUS AND FUTURE PERSPECTIVES

  2018cited by this paper
• A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

  2017cited by this paper
• Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI‐906) or Placebo in Chemotherapy‐Naive Patients With Non–Small‐Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

  2017cited by this paper
• Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies

  2017cited by this paper
• IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.

  2016cited by this paper
• Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.

  2016cited by this paper
• IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.

  2016cited by this paper
• Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity

  2016cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer

  2016cited by this paper
• Phase I dose escalation (esc) trial of weekly intravenous (i.v.) BI 836845 in Japanese patients (pts) with advanced solid tumors

  2016cited by this paper
• Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results.

  2016cited by this paper
• The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas

  2016cited by this paper
• Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer

  2016cited by this paper
• Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.

  2016cited by this paper
• miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway

  2016cited by this paper
• Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

  2016cited by this paper
• Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.

  2016cited by this paper
• A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC).

  2016cited by this paper
• Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling

  2016cited by this paper
• Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells

  2016cited by this paper
• Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor

  2016cited by this paper
• Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

  2016cited by this paper
• Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC

  2016cited by this paper
• Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer

  2016cited by this paper
• TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1

  2016cited by this paper
• Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX

  2016cited by this paper
• Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer

  2016cited by this paper
• IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin

  2016cited by this paper
• A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

  2016cited by this paper
• Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies

  2015influential reference
• Crosstalk of the Insulin-Like Growth Factor Receptor with the Wnt Signaling Pathway in Breast Cancer

  2015cited by this paper
• Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours

  2015cited by this paper
• Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer

  2015cited by this paper
• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

  2015cited by this paper
• Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.

  2015cited by this paper
• IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

  2015cited by this paper
• Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cited by this paper
• The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link

  2015cited by this paper
• Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

  2015cited by this paper
• ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents

  2015cited by this paper
• Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer

  2015cited by this paper
• IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma

  2015cited by this paper
• InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma

  2015cited by this paper
• IGF-IR: a new prognostic biomarker for human glioblastoma

  2015influential reference
• Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 Receptor-insulin receptor substrate and STAT3 signaling

  2015cited by this paper
• Abstract CT237: Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3

  2015cited by this paper
• Involvement of IGF-1 and Akt in M1/M2 activation state in bone marrow-derived macrophages.

  2015cited by this paper
• Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

  2015cited by this paper
• Disruption of insulin receptor function inhibits proliferation in endocrine resistant breast cancer cells

  2015cited by this paper
• Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors

  2015cited by this paper
• Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.

  2015cited by this paper
• A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Abstract 420: The role of tumor microenvironment in therapy resistance and melanoma progression

  2015cited by this paper
• A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• EMT and tumor metastasis

  2015cited by this paper
• A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

  2015cited by this paper
• Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

  2015cited by this paper
• A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

  2015cited by this paper
• Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC)

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial

  2014cited by this paper
• Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease

  2014cited by this paper
• Crosstalk between IGF-1R and other tumor promoting pathways.

  2014influential reference
• A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

  2014cited by this paper
• Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

  2014cited by this paper
• Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

  2014influential reference
• A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

  2014cited by this paper
• Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma

  2014cited by this paper
• Universes collide: combining immunotherapy with targeted therapy for cancer.

  2014cited by this paper
• CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.

  2014cited by this paper
• Insulin-like growth factor-1 induces regulatory T cell-mediated suppression of allergic contact dermatitis in mice

  2014cited by this paper
• IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors.

  2014cited by this paper
• Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

  2014cited by this paper
• The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents

  2014cited by this paper
• Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

  2014cited by this paper
• The Emerging Role of Insulin and Insulin-Like Growth Factor Signaling in Cancer Stem Cells

  2014cited by this paper
• miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

  2014cited by this paper
• Increased miR‐223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin‐like growth factor‐1‐mediated interleukin‐10 production

  2014cited by this paper
• Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

  2014cited by this paper
• A phase I dose escalation study of weekly BI 836845, a fully human, affinity-optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid cancers.

  2014cited by this paper
• Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance

  2014influential reference
• Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

  2014cited by this paper
• The insulin‐like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild‐type epidermal growth factor receptor

  2014influential reference
• MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas

  2014cited by this paper
• Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

  2014cited by this paper
• IGF binding proteins in cancer: mechanistic and clinical insights

  2014cited by this paper
• Can we unlock the potential of IGF-1R inhibition in cancer therapy?

  2014influential reference
• First-in-human study of MM-141: A novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3.

  2014cited by this paper
• An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

  2013cited by this paper
• Cancer Genome Landscapes

  2013cited by this paper
• Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

  2013cited by this paper
• MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

  2013cited by this paper
• Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation

  2013cited by this paper
• Targeting the insulin-like growth factor-1 receptor in human cancer

  2013cited by this paper
• Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

  2013cited by this paper

• Epithelial and stromal remodelling in murine Crohn’s disease-like ileitis

  2026cites this paper
• Oncogenesis in cholangiocarcinoma.

  2026cites this paper
• Styrylquinoline Derivatives as IGF1R Inhibitors.

  2026cites this paper
• Fasting-mimicking diets as a strategy to reprogram tumor metabolism: a systematic review

  2026cites this paper
• Epithelial and stromal remodeling in murine Crohn’s disease-like ileitis

  2025cites this paper
• Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer

  2025cites this paper
• Growth hormone in disease and treatment (Review)

  2025cites this paper
• Receptor-mediated nose-to-brain delivery of drug combination-loaded polymeric nanocarriers for the treatment of glioblastoma- current progress and future perspectives part I: receptor-mediated nose-to-brain delivery approaches for glioblastoma

  2025cites this paper
• Detection of Genome‐Wide IGF‐1R Recruitment to Enhancer and Promoter Regions of Chromatin in Clinical Prostate Cancers

  2025cites this paper
• Genetic predisposition to persistent fatigue after a diagnosis of colorectal cancer

  2025cites this paper
• Expression of IGF-1R in the Surface Epithelium Versus Invasive Front across Different Grades of Oral Squamous Cell Carcinoma: an Immunohistochemistry Analysis

  2025cites this paper
• Precision medicine, insulin-like growth factors and cancer therapy

  2025cites this paper
• Advances in the role of the IGF signaling system in myelodysplastic syndromes and acute myeloid leukemia

  2025cites this paper
• IGF-1R Inhibitors in Cancer: A Review of Available Evidence and Future Outlook.

  2025cites this paper
• Glioblastoma: molecular features, emerging molecular targets and novel therapeutic strategies.

  2025cites this paper
• Molecular Targets in Alveolar Rhabdomyosarcoma: A Narrative Review of Progress and Pitfalls

  2025cites this paper
• Recent Issues in the Development and Application of Targeted Therapies with Respect to Individual Animal Variability

  2025cites this paper
• From in silico prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells

  2025cites this paper
• Restricting lipid accumulation in tumor-infiltrating neutrophils mediates caloric restriction-induced anti-cancer effects.

  2025cites this paper
• Association between Expression of Insulin-like Growth Factor-1 (IGF-1), IGF-1 Receptor (IGF-1R), and Hypertension-Mediated Organ Damage (HMOD) Parameters in Leukocytes and Plasma of Children/Adolescents with Primary Hypertension

  2024cites this paper
• Inhibition of Insulin-like Growth Factor 1 Receptor/Insulin Receptor Signaling by Small-Molecule Inhibitor BMS-754807 Leads to Improved Survival in Experimental Esophageal Adenocarcinoma

  2024cites this paper
• Decoding the Role of Insulin-like Growth Factor 1 and Its Isoforms in Breast Cancer

  2024influential citation
• Role of PRMT1 and PRMT5 in Breast Cancer

  2024cites this paper
• Anti-PEc: Development of a novel monoclonal antibody against prostate cancer

  2024cites this paper
• Insulin-like growth factor family and prostate cancer: new insights and emerging opportunities

  2024cites this paper
• Regulatory mechanisms and regeneration strategies of the soft–hard tissue interface in the human periodontium

  2024cites this paper
• Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia

  2023cites this paper
• THE RELATIONSHIP BETWEEN DIABETES MELLITUS AND PANCREATIC CANCER - DIABETES MELLITUS AS A RED FLAG FOR PANCREATIC CANCER.

  2023cites this paper
• Review: The PI3K-AKT-mTOR signal transduction pathway in canine cancer

  2023cites this paper
• Insulin-like growth factors and aging: lessons from Laron syndrome

  2023cites this paper
• The IGF1 Signaling Pathway: From Basic Concepts to Therapeutic Opportunities

  2023cites this paper
• XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

  2023cites this paper
• Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells

  2023cites this paper
• Higher levels of insulin‐like growth factor‐1 in cord blood associate with risk of asthma at age 3

  2023cites this paper
• Mutual connected IL-6, EGFR and LIN28/Let7-related mechanisms modulate PD-L1 and IGF upregulation in HNSCC using immunotherapy

  2023cites this paper
• Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer

  2022cites this paper
• Activation of Oncogenic and Immune-Response Pathways Is Linked to Disease-Specific Survival in Merkel Cell Carcinoma

  2022cites this paper
• Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell–Cell Interactions That Predict Immunotherapy Response

  2022cites this paper
• Phase Ib Trial of Xentuzumab Combined with Abemaciclib in Patients with Advanced Solid Tumors, Including Its Use Alongside Endocrine Therapy in Advanced Breast Cancer

  2022cites this paper
• Identification of a stretch of four discontinuous amino acids involved in regulating kinase activity of IGF1R.

  2022cites this paper
• The Role of ARID1A in the Nonestrogenic Modulation of IGF-1 Signaling

  2022cites this paper
• An insulin growth factor-I/II-neutralizing monoclonal antibody in combination with epidermal growth factor receptor inhibitors potently inhibits tumor cell growth

  2022cites this paper
• Decoding Insulin-Like Growth Factor Signaling Pathway From a Non-coding RNAs Perspective: A Step Towards Precision Oncology in Breast Cancer

  2022cites this paper
• Potential therapeutic strategies to combat HCC.

  2022cites this paper
• Molecular regulation of phenolic compounds on IGF-1 signaling cascade in breast cancer.

  2022cites this paper
• Obesity and Thyroid Cancer Risk: An Update

  2022cites this paper
• Thyroid gland cancer and insulin resistance: a modern view of the problem

  2022cites this paper
• Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier

  2022cites this paper
• Hallmarks of cancer: The insulin-like growth factors perspective

  2022cites this paper
• Interaction of a viral insulin-like peptide with the IGF-1 receptor produces a natural antagonist

  2022cites this paper
• Impact of the host response and osteoblast lineage cells on periodontal disease

  2022cites this paper
• Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models

  2022cites this paper
• Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma

  2022cites this paper
• Evaluation of Metabolic Syndrome as A Risk Factor for Colorectal Cancer

  2021cites this paper
• Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor

  2021cites this paper
• A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

  2021cites this paper
• Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma

  2021cites this paper
• Controlled Signaling—Insulin-Like Growth Factor Receptor Endocytosis and Presence at Intracellular Compartments

  2021cites this paper
• Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

  2021influential citation
• Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports

  2021cites this paper
• Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?

  2021cites this paper
• Translational cell biology of highly malignant osteosarcoma

  2021cites this paper
• Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme

  2021cites this paper
• Growth Hormone/Insulin Growth Factor Axis in Sex Steroid Associated Disorders and Related Cancers

  2021cites this paper
• Knockdown of TMED3 inhibits cell viability and migration and increases apoptosis in human chordoma cells

  2021cites this paper
• Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming

  2021cites this paper
• Breast Cancer and the Other Non-Coding RNAs

  2021cites this paper
• Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

  2021cites this paper
• IGF-1R nuclear import and recruitment to chromatin involves both alpha and beta subunits

  2021cites this paper
• Targeting obesity-related dysfunction in hormonally driven cancers

  2021cites this paper
• RE-VISITED; ARE FOODS FRIEND OR FOE FOR CANCER?

  2021cites this paper
• Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients

  2021cites this paper
• The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis

  2021cites this paper
• Pathophysiological Characteristics Linking Type 2 Diabetes Mellitus and Colorectal Neoplasia.

  2021cites this paper
• Targeting the HIF-1α-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor

  2021cites this paper
• Gastric Cancer: Identification of microRNAs Inhibiting Druggable Targets and Mediating Efficacy in Preclinical In Vivo Models

  2021cites this paper
• Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control

  2021influential citation
• Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells

  2021cites this paper
• Partial EMT in head and neck cancer biology: a spectrum instead of a switch

  2021cites this paper
• Body size and composition and risk of site-specific cancers in the UK Biobank and large international consortia: A mendelian randomisation study

  2021cites this paper
• Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma.

  2021cites this paper
• Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer

  2021cites this paper
• GH and IGF System: The Regulatory Role of miRNAs and lncRNAs in Cancer

  2021cites this paper
• Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options

  2021influential citation
• INSULIN-LIKE GROWTH FACTORS IN THE SERUM OF PATIENTS WITH PAPILLARY THYROID CANCER.

  2021cites this paper
• Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

  2021cites this paper
• Extracting Potential New Targets for Treatment of Adenoid Cystic Carcinoma using Bioinformatic Methods

  2021cites this paper
• Insulin-like growth factor-1

  2021cites this paper
• A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma

  2021cites this paper
• Obesity, Diabetes, and Increased Cancer Progression

  2021cites this paper
• A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors

  2021cites this paper
• Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways

  2021cites this paper
• IGFBP2 Is a Potential Master Regulator Driving the Dysregulated Gene Network Responsible for Short Survival in Glioblastoma Multiforme

  2020cites this paper
• Computational response modeling reveals context dependent Akt activity in luminal breast cancer cells

  2020cites this paper
• Assessment of IGF-1 expression in the peripheral blood of women with recurrent breast cancer

  2020cites this paper
• Cancer and Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy Carrying a Common IGF1R Variant.

  2020cites this paper
• Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma

  2020cites this paper
• Osteoidbildende Knochentumoren

  2020cites this paper
• 3D interactions with the GH locus in cellular signalling and cancer-related pathways.

  2020cites this paper
• Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

  2020cites this paper